ARS Pharmaceuticals (SPRY) Expected to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $41.99 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The business had revenue of $33.66 million for the quarter, compared to the consensus estimate of $31.32 million. On average, analysts expect ARS Pharmaceuticals to post ($1.91) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ:SPRY opened at $3.05 on Wednesday. ARS Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $13.15. The stock’s fifty day simple moving average is $4.48 and its two-hundred day simple moving average is $7.34. The stock has a market cap of $303.32 million, a PE ratio of -1.40 and a beta of 0.98. The company has a current ratio of 3.48, a quick ratio of 3.28 and a debt-to-equity ratio of 13.72.

Analyst Ratings Changes

SPRY has been the topic of several research reports. Leerink Partners set a $15.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, September 8th. Weiss Ratings lowered shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $23.33.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.